- Home
- SKYA vs CNTX Comparison
SKYA vs CNTX Comparison
Compare SKYA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKYA | CNTX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.7M | 47.7M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKYA | CNTX |
|---|---|---|
| Price | $1.88 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 313.9K | ★ 1.1M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,120.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.91 | $0.32 |
| 52 Week High | $1.96 | $3.62 |
Technical Indicators
Market Signals| Indicator | SKYA | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.68 | 29.42 |
| Support Level | $0.97 | N/A |
| Resistance Level | N/A | $0.40 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 88.51 | 5.24 |
Price Performance
Historical ComparisonAbout SKYA SkyAI Inc. Common Stock
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.